in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
AMRI Signs Development and Manufacturing Deal with Australian Firm
6:25 AM MDT | April 17, 2012 | Deepti Ramesh
Albany Molecular Research Inc. (AMRI; Albany, NY) says it was selected by Biota (Melbourne Australia), a leading anti-infective drug development company, to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. AMRI will provide these services to support a new drug application for laninamivir to the U.S. Food and Drug Administration (FDA). AMRI's role will initially involve the development and manufacture of the active pharmaceutical ingredient (API) for use in clinical trials. In...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee